TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06638502: Safety of HRX215 in Patients After Minor and Major Liver Resection

Sponsor: HepaRegeniX GmbH · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$2,159,850

Rescue Site Savings

+$1,413,720

Unlock Full NCT06638502 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06638502 Rescue Dossier →